A Phase I/II Open-label Trial of Intravenous CAVATAK^TM in Combination With Pembrolizumab for the Treatment of Patients With Advanced NSCLC
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2016
At a glance
- Drugs CVA 21 (Primary) ; Pembrolizumab
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Viralytics
- 07 Jun 2017 Biomarkers information updated
- 06 Jul 2016 Status changed from planning to not yet recruiting.
- 17 Mar 2016 This trial is expected to begin in 2016, according to a Viralytics media release.